PL2170340T3 - Sposoby i kompozycje stymulacji neurogenezy i hamowania degeneracji neuronów z wykorzystaniem izotiazolopirymidonów - Google Patents

Sposoby i kompozycje stymulacji neurogenezy i hamowania degeneracji neuronów z wykorzystaniem izotiazolopirymidonów

Info

Publication number: PL2170340T3
Authority: PL; Poland
Prior art keywords: isothiazolopyrimidinones; compositions; methods; neuronal degeneration; inhibiting neuronal
Prior art date: 2007-06-21

Application number

PL08771642T

Other languages

English (en)

Inventor

Anderson Judith Kelleher

Original Assignee

Neuronascent Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-21

Filing date

2008-06-20

Publication date

2016-06-30

2008-06-20 Application filed by Neuronascent Inc filed Critical Neuronascent Inc

2016-06-30 Publication of PL2170340T3 publication Critical patent/PL2170340T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Addiction (AREA)
Epidemiology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Nutrition Science (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

PL08771642T 2007-06-21 2008-06-20 Sposoby i kompozycje stymulacji neurogenezy i hamowania degeneracji neuronów z wykorzystaniem izotiazolopirymidonów PL2170340T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US94552407P	2007-06-21	2007-06-21
PCT/US2008/067742 WO2008157791A2 (en)	2007-06-21	2008-06-20	Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
EP08771642.9A EP2170340B1 (en)	2007-06-21	2008-06-20	Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones

Publications (1)

Publication Number	Publication Date
PL2170340T3 true PL2170340T3 (pl)	2016-06-30

Family

ID=40156978

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL08771642T PL2170340T3 (pl)	2007-06-21	2008-06-20	Sposoby i kompozycje stymulacji neurogenezy i hamowania degeneracji neuronów z wykorzystaniem izotiazolopirymidonów

Country Status (13)

Country	Link
US (3)	US8609840B2 (pl)
EP (2)	EP3053584A1 (pl)
JP (4)	JP2010530898A (pl)
KR (2)	KR101565971B1 (pl)
CN (1)	CN101842100A (pl)
AU (1)	AU2008265600B2 (pl)
CA (1)	CA2693062C (pl)
DK (1)	DK2170340T3 (pl)
ES (1)	ES2564826T3 (pl)
IL (2)	IL202485A (pl)
PL (1)	PL2170340T3 (pl)
RU (1)	RU2521333C2 (pl)
WO (1)	WO2008157791A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2170340T3 (pl) *	2007-06-21	2016-06-30	Neuronascent Inc	Sposoby i kompozycje stymulacji neurogenezy i hamowania degeneracji neuronów z wykorzystaniem izotiazolopirymidonów
CN102177152A (zh)	2008-08-11	2011-09-07	哈佛大学校长及研究员协会	用于抑制tRNA合成酶的卤夫酮(halofuginone)类似物和其用途
AU2010298440B2 (en) *	2009-09-22	2016-05-19	Neuronascent, Inc	Methods and pharmaceutical compositions for treating down syndrome
WO2013106702A1 (en)	2012-01-13	2013-07-18	President And Fellows Of Harvard College	Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
US9944644B2 (en)	2013-03-14	2018-04-17	The Trustees Of Columbia University In The City Of New York	Octahydropyrrolopyrroles their preparation and use
ES2705247T3 (es)	2013-03-14	2019-03-22	Univ Columbia	4-fenilpiperidinas, su preparación y uso
WO2014151959A1 (en)	2013-03-14	2014-09-25	The Trustees Of Columbia University In The City Of New York	N-alkyl-2-phenoxyethanamines, their preparation and use
WO2014152018A1 (en)	2013-03-14	2014-09-25	The Trustees Of Columbia University In The City Of New York	Octahydrocyclopentapyrroles, their preparation and use
BR112016025356B1 (pt)	2014-04-30	2023-04-18	The Trustees Of Columbia University In The City Of New York	Compostos de 4-fenilpiperidinas substituídas, composições e seus usos
RU2613765C1 (ru) *	2016-01-26	2017-03-21	Федеральное государственное автономное образовательное учреждение высшего образования "Северо-Восточный федеральный университет им. М.К.Аммосова"	Способ лечения спиноцеребеллярной атаксии
US10064833B2 (en) *	2016-08-04	2018-09-04	Syneurx International (Taiwan) Corp.	Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
RU2670128C2 (ru) *	2016-12-16	2018-10-18	Федеральное государственное автономное образовательное учреждение высшего образования "Балтийский федеральный университет имени Иммануила Канта" (БФУ им. И. Канта)	Способ генетической регистрации и коррекции нейрогенеза на основе генетических конструкций для трансфекции нейронов
RU2675111C2 (ru) *	2017-03-31	2018-12-17	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии"	Способ стимуляции нейрогенеза в гиппокампе
CN111093375A (zh) *	2017-07-03	2020-05-01	拜耳作物科学股份公司	新的基于异噻唑并结构的双环、其制备方法及其用作除草剂和/或植物生长调节剂的用途
EP3801525A4 (en)	2018-06-08	2022-03-23	The General Hospital Corporation	PROLYL TRNA SYNTHETASE INHIBITORS

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en) *	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
CH588887A5 (pl)	1974-07-19	1977-06-15	Battelle Memorial Institute
US4089809A (en) *	1976-03-01	1978-05-16	The United States Of America As Represented By The United States Department Of Energy	Regenerable sorbent and method for removing hydrogen sulfide from hot gaseous mixtures
US4233871A (en) *	1978-04-26	1980-11-18	Alessi Anthony A	Notching tool
EP0032578B1 (de) *	1980-01-16	1984-07-25	Hans Georg Prof. Dr. Weder	Verfahren und Dialysiereinrichtung zur Herstellung von Bilayer-Vesikeln und Verwendung der Bilayer-Vesikel
US4485054A (en) *	1982-10-04	1984-11-27	Lipoderm Pharmaceuticals Limited	Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4438253A (en)	1982-11-12	1984-03-20	American Cyanamid Company	Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
JPS60100516A (ja) *	1983-11-04	1985-06-04	Takeda Chem Ind Ltd	徐放型マイクロカプセルの製造法
US4532089A (en) *	1984-01-14	1985-07-30	Northwestern University	Method of preparing giant size liposomes
US4897269A (en)	1984-09-24	1990-01-30	Mezei Associates Limited	Administration of drugs with multiphase liposomal delivery system
JP2670680B2 (ja) *	1988-02-24	1997-10-29	株式会社ビーエムジー	生理活性物質含有ポリ乳酸系微小球およびその製造法
US5580575A (en)	1989-12-22	1996-12-03	Imarx Pharmaceutical Corp.	Therapeutic drug delivery systems
US5820880A (en)	1995-06-07	1998-10-13	The United States Of America As Represented By The Secretary Of The Army	Liposomal formulation
US5665428A (en) *	1995-10-25	1997-09-09	Macromed, Inc.	Preparation of peptide containing biodegradable microspheres by melt process
US5736152A (en)	1995-10-27	1998-04-07	Atrix Laboratories, Inc.	Non-polymeric sustained release delivery system
US6287588B1 (en) *	1999-04-29	2001-09-11	Macromed, Inc.	Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
BR0010316A (pt) *	1999-05-11	2004-04-27	Ortho Mcnell Pharmaceutical In	Método e sistema para obtenção de regimes de dosagem otimizados de epo para uma resposta farmacodinâmica/farmacocinética desejada em um paciente
ES2326647T3 (es)	2003-03-07	2009-10-16	Astrazeneca Ab	Heterociclos condensados y sus usos.
DK1475094T3 (da)	2003-05-06	2010-11-22	Univ Palackeho	Pyrazolo[4,3-d]pyrimidiner, fremgangsmåde til deres fremstilling samt deres anvendelse
US7022850B2 (en) *	2003-05-22	2006-04-04	Bristol-Myers Squibb Co.	Bicyclicpyrimidones and their use to treat diseases
AR050921A1 (es) *	2004-08-18	2006-12-06	Astrazeneca Ab	Heterociclos fusionados seleccionados y usos de los mismos
WO2007030697A2 (en) *	2005-09-07	2007-03-15	Braincells, Inc.	Modulation of neurogenesis by hdac inhibition
PL2170340T3 (pl) *	2007-06-21	2016-06-30	Neuronascent Inc	Sposoby i kompozycje stymulacji neurogenezy i hamowania degeneracji neuronów z wykorzystaniem izotiazolopirymidonów

2008
- 2008-06-20 PL PL08771642T patent/PL2170340T3/pl unknown
- 2008-06-20 WO PCT/US2008/067742 patent/WO2008157791A2/en not_active Ceased
- 2008-06-20 CN CN200880021069A patent/CN101842100A/zh active Pending
- 2008-06-20 US US12/664,995 patent/US8609840B2/en active Active
- 2008-06-20 EP EP16155774.9A patent/EP3053584A1/en not_active Withdrawn
- 2008-06-20 DK DK08771642.9T patent/DK2170340T3/en active
- 2008-06-20 KR KR1020107001298A patent/KR101565971B1/ko active Active
- 2008-06-20 JP JP2010513461A patent/JP2010530898A/ja active Pending
- 2008-06-20 KR KR1020157008401A patent/KR101600054B1/ko not_active Expired - Fee Related
- 2008-06-20 AU AU2008265600A patent/AU2008265600B2/en not_active Ceased
- 2008-06-20 RU RU2010100945/15A patent/RU2521333C2/ru active
- 2008-06-20 ES ES08771642.9T patent/ES2564826T3/es active Active
- 2008-06-20 CA CA2693062A patent/CA2693062C/en active Active
- 2008-06-20 EP EP08771642.9A patent/EP2170340B1/en active Active
2009
- 2009-12-03 IL IL202485A patent/IL202485A/en not_active IP Right Cessation
2013
- 2013-11-13 US US14/079,489 patent/US9096613B2/en active Active
2014
- 2014-05-15 JP JP2014101014A patent/JP5850981B2/ja active Active
2015
- 2015-06-16 JP JP2015121083A patent/JP6081528B2/ja active Active
- 2015-06-26 US US14/751,403 patent/US9592234B2/en active Active
2017
- 2017-01-18 JP JP2017006944A patent/JP2017066166A/ja active Pending
- 2017-03-14 IL IL251169A patent/IL251169A0/en unknown

Also Published As

Publication number	Publication date
IL251169A0 (en)	2017-04-30
KR101565971B1 (ko)	2015-11-05
US9096613B2 (en)	2015-08-04
US20140171428A1 (en)	2014-06-19
EP2170340B1 (en)	2016-02-24
CA2693062C (en)	2016-08-09
IL202485A0 (en)	2010-06-30
KR20100040728A (ko)	2010-04-20
JP2017066166A (ja)	2017-04-06
JP5850981B2 (ja)	2016-02-03
AU2008265600B2 (en)	2013-10-31
RU2010100945A (ru)	2011-07-27
US8609840B2 (en)	2013-12-17
WO2008157791A3 (en)	2009-12-30
US20160022682A1 (en)	2016-01-28
WO2008157791A2 (en)	2008-12-24
CN101842100A (zh)	2010-09-22
JP2015163648A (ja)	2015-09-10
JP2010530898A (ja)	2010-09-16
EP3053584A1 (en)	2016-08-10
DK2170340T3 (en)	2016-03-14
EP2170340A2 (en)	2010-04-07
AU2008265600A1 (en)	2008-12-24
RU2521333C2 (ru)	2014-06-27
US20100298318A1 (en)	2010-11-25
EP2170340A4 (en)	2010-12-08
JP6081528B2 (ja)	2017-02-15
KR20150041668A (ko)	2015-04-16
KR101600054B1 (ko)	2016-03-04
US9592234B2 (en)	2017-03-14
JP2014196308A (ja)	2014-10-16
ES2564826T3 (es)	2016-03-29
CA2693062A1 (en)	2008-12-24
IL202485A (en)	2017-03-30

Publication	Publication Date	Title
IL251169A0 (en)	2017-04-30	Methods and preparations for stimulating the generation of nerve cells and inhibiting the degeneration of nerve cells through the use of isothiazolopyrimidinones
HRP20182135T1 (hr)	2019-03-22	Pripravci za i postupci liječenja poremećaja povezanih s ige
EP2170309A4 (en)	2010-11-03	METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
ZA201001810B (en)	2011-05-25	Seed treatment compositions and methods
ZA201001811B (en)	2011-05-25	Seed treatment compositions and methods
PL2187880T3 (pl)	2014-05-30	Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej
IL205704A0 (en)	2010-11-30	Compositions and methods for treating purpura
IL209032A0 (en)	2011-01-31	Compositions and methods for treating digestive disorders
IL202329A0 (en)	2010-06-30	Methods and compositions for stimulating cells
IL202015A0 (en)	2010-06-16	Methods and compositions for treating skin conditions
IL241928A0 (en)	2015-11-30	Preparations and methods for the treatment of muscle diseases
EP2120561A4 (en)	2012-11-21	COMPOSITIONS FOR TREATING BIOFILMS, AND METHODS FOR THEIR USE
ZA201001300B (en)	2010-11-24	Antigen-asjuvant compositions and methods
GB2466912B (en)	2012-01-04	Compositions and methods for treating lysosomal disorders
EP2205255A4 (en)	2012-02-29	VEGETABLE COMPOSITIONS AND METHOD FOR THE TREATMENT OF HEPATITIC ILLNESSES
IL210097A0 (en)	2011-02-28	Compositions and methods for treating unfluenza
IL198723A0 (en)	2010-02-17	Methods and compositions for therapeutic treatment
GB0721291D0 (en)	2007-12-12	Methods and compositions
HUP0700369D0 (en)	2007-07-30	Pharmaceutical compositions and method for treating schizofrenia
HRP20130642T1 (en)	2013-08-31	Methods and compositions for treating cancers
GB0719526D0 (en)	2007-11-14	Compositions and methods
PL1937252T3 (pl)	2018-01-31	Kompozycje do stymulowania neurogenezy oraz hamowania degeneracji neuronów
IL173971A0 (en)	2006-07-05	Compositions and methods for treating and preventing age-related macular degeneration
GB0419295D0 (en)	2004-09-29	Methods and compositions to prevent neuronal degeneration
GB0714500D0 (en)	2007-09-05	composition and treatment